In lung cancers, IL-34 triggers activation of CCAAT/enhancer-binding protein β via AKT-mediated pathway with the downstream effect of enhancing the pro-tumorigenic and immunosuppressive functions of TAMs and consequently promoting the survival of chemoresistant cancer cells [36]. The gene discussed is IL34; the disease is lung cancer.